ASH 2024 | The growing importance of bispecific antibodies in the treatment of multiple myeloma

The bispecifics, what we preach from our center to our colleagues is they’re here. They’re here. They’re not only are they here in the relapse setting, they’re going to be part, in my opinion, of the upfront therapy of myeloma very, very quickly. So everyone needs to get facile with administering bispecifics in myeloma and managing the side effects. And so I think there are a lot of questions still to be asked, but we’re going to be using them in frontline, perhaps in maintenance therapy. There’s a trial in high-risk smoldering disease with bispecifics. And so they are here, and they’re not going anywhere for a while. They’re super effective. We saw an abstract yesterday with a combination of teclistamab, daratumumab, and pomalidomide to treat treatment-naive patients as part of the MajesTEC-2 trial and the TRIMM trial. And what we saw is remarkable, which is all patients MRD negative early. And so the bispecifics, I think, are super. We need to learn the right schedule. We need to learn for the BCMA bispecifics in particular how to manage and mitigate infection risk. And for the GPRC5D bispecifics, in this case talquetamab, we need to learn how to better manage the off-tumor on-target side effects. You know, dyskinesia, skin rash, and that kind of thing. So lots still to be learned. But the bispecifics are here and it’s a great thing for patients. We all just need to get on board.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.